Understanding and altering cell tropism of vesicular stomatitis virus

Virus Research

Volumn 176, Issue 1-2, 2013, Pages 16-32

  Hastie, Eric ^a   Cataldi, Marcela ^a   Marriott, Ian ^a   Grdzelishvili, Valery Z ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

Host factors; Neurotoxicity; Neurotropism; Oncolytic; Tropism; Vesicular stomatitis virus; VSV

Indexed keywords

ACTIN; CALNEXIN; CASEIN KINASE II; CHAPERONIN 60; CYCLOPHILIN A; DYNAMIN I; ELONGATION FACTOR 1ALPHA; GLYCOPROTEIN; HEAT SHOCK PROTEIN 90; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PATTERN RECOGNITION RECEPTOR; TATA BINDING PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VIRUS VECTOR;

APOPTOSIS; BASIC RESEARCH; CELL DEATH; CELL GROWTH; CELL TYPE; ENDOSOME; ENZYME ACTIVITY; GENE; GENETIC TRANSDUCTION; IMMUNE EVASION; INNATE IMMUNITY; MITOCHONDRIAL MEMBRANE; NEUROTOXICITY; NEUROTROPISM; NONHUMAN; PERMEABILITY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOTYPING; REVIEW; SIGNAL TRANSDUCTION; TETRATRICOPEPTIDE REPEAT; THERAPY EFFECT; TROPISM; VESICULAR STOMATITIS VIRUS; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALIA; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 84881370767     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.06.003     Document Type: Review

References (260)

1. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
2. Ammayappan A., Nace R., Peng K.W., Russell S.J. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J. Virol. 2013, 87:3217-3228.
3. Ayala-Breton C., Barber G.N., Russell S.J., Peng K.W. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum. Gene Ther. 2012, 23:484-491.
4. Balachandran S., Barber G.N. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004, 5:51-65.
5. Barber G.N. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 2004, 17:516-527.
6. Barik S., Banerjee A.K. Phosphorylation by cellular casein kinase II is essential for transcriptional activity of vesicular stomatitis virus phosphoprotein P. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6570-6574.
7. Barna M., Komatsu T., Bi Z., Reiss C.S. Sex differences in susceptibility to viral infection of the central nervous system. J. Neuroimmunol. 1996, 67:31-39.
8. Basu M., Maitra R.K., Xiang Y., Meng X., Banerjee A.K., Bose S. Inhibition of vesicular stomatitis virus infection in epithelial cells by alpha interferon-induced soluble secreted proteins. J. Gen. Virol. 2006, 87:2653-2662.
9. Bauer J., Huitinga I., Zhao W., Lassmann H., Hickey W.F., Dijkstra C.D. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 1995, 15:437-446.
10. Bergman I., Griffin J., Gao Y., Whitaker-Dowling P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int. J. Cancer 2007, 121:425-430.
11. Bergold G.H., Suarez O.M., Munz K. Multiplication in and transmission by Aedes aegypti of vesicular stomatitis virus. J. Invertebr. Pathol. 1968, 11:406-428.
12. Bi Z., Barna M., Komatsu T., Reiss C.S. Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J. Virol. 1995, 69:6466-6472.
13. Bi Z., Quandt P., Komatsu T., Barna M., Reiss C.S. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. J. Immunol. 1995, 155:5684-5689.
14. Black B.L., Rhodes R.B., McKenzie M., Lyles D.S. The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J. Virol. 1993, 67:4814-4821.
15. Bloor S., Maelfait J., Krumbach R., Beyaert R., Randow F. Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6970-6975.
16. Boon J.M., Smith B.D. Chemical control of phospholipid distribution across bilayer membranes. Med. Res. Rev. 2002, 22:251-281.
17. Bose S., Mathur M., Bates P., Joshi N., Banerjee A.K. Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype. J. Gen. Virol. 2003, 84:1687-1699.
18. Boudreau J.E., Bridle B.W., Stephenson K.B., Jenkins K.M., Brunelliere J., Bramson J.L., Lichty B.D., Wan Y. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther. 2009, 17:1465-1472.
19. Brown C.W., Stephenson K.B., Hanson S., Kucharczyk M., Duncan R., Bell J.C., Lichty B.D. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J. Virol. 2009, 83:552-561.
20. Browning M.J., Huneycutt B.S., Huang A.S., Reiss C.S. Replication-defective viruses modulate immune responses. J. Immunol. 1991, 147:2685-2691.
21. Bukreyev A., Skiadopoulos M.H., Murphy B.R., Collins P.L. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 2006, 80:10293-10306.
22. Carneiro F.A., Bianconi M.L., Weissmuller G., Stauffer F., Da Poian A.T. Membrane recognition by vesicular stomatitis virus involves enthalpy-driven protein-lipid interactions. J. Virol. 2002, 76:3756-3764.
23. Carneiro F.A., Lapido-Loureiro P.A., Cordo S.M., Stauffer F., Weissmuller G., Bianconi M.L., Juliano M.A., Juliano L., Bisch P.M., Da Poian A.T. Probing the interaction between vesicular stomatitis virus and phosphatidylserine. Eur. Biophys. J. 2006, 35:145-154.
24. Cary Z.D., Willingham M.C., Lyles D.S. Oncolytic vesicular stomatitis virus induces apoptosis in U87 Glioblastoma Cells by a Type II Death receptor mechanism and induces cell death and tumor clearance in vivo. J. Virol. 2011, 85:5708-5717.
25. Cave D.R., Hendrickson F.M., Huang A.S. Defective interfering virus particles modulate virulence. J. Virol. 1985, 55:366-373.
26. Chang G., Xu S., Watanabe M., Jayakar H.R., Whitt M.A., Gingrich J.R. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. J. Urol. 2010, 183:1611-1618.
27. Chauhan V.S., Sterka D.G., Furr S.R., Marriott I., Grdzelishvili V.Z. Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology 2010.
28. Chen L., Zhang S., Banerjee A.K., Chen M. N-terminal phosphorylation of phosphoprotein of vesicular stomatitis virus (VSV) is required for preventing nucleoprotein from binding to cellular RNAs and for functional template formation. J. Virol. 2013.
29. Chen N., Restivo A., Reiss C.S. Leukotrienes play protective roles early during experimental VSV encephalitis. J. Neuroimmunol. 2001, 120:94-102.
30. Chen N., Warner J.L., Reiss C.S. NSAID treatment suppresses VSV propagation in mouse CNS. Virology 2000, 276:44-51.
31. Christian A.Y., Barna M., Bi Z., Reiss C.S. Host immune response to vesicular stomatitis virus infection of the central nervous system in C57BL/6 mice. Viral Immunol. 1996, 9:195-205.
32. Clemens M.J., Vaquero C.M. Inhibition of protein synthesis by double-stranded RNA in reticulocyte lysates: evidence for activation of an endoribonuclease. Biochem. Biophys. Res. Commun. 1978, 83:59-68.
33. Coil D.A., Miller A.D. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J. Virol. 2004, 78:10920-10926.
34. Coll J.M. Heptad-repeat sequences in the glycoprotein of rhabdoviruses. Virus Genes 1995, 10:107-114.
35. Coll J.M. Synthetic peptides from the heptad repeats of the glycoproteins of rabies, vesicular stomatitis and fish rhabdoviruses bind phosphatidylserine. Arch. Virol. 1997, 142:2089-2097.
36. Colonno R.J., Lazzarini R.A., Keene J.D., Banerjee A.K. In vitro synthesis of messenger RNA by a defective interfering particle of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:1884-1888.
37. Compton T., Ivanov I.E., Gottlieb T., Rindler M., Adesnik M., Sabatini D.D. A sorting signal for the basolateral delivery of the vesicular stomatitis virus (VSV) G protein lies in its luminal domain: analysis of the targeting of VSV G-influenza hemagglutinin chimeras. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:4112-4116.
38. Connor J.H., Lyles D.S. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J. Virol. 2002, 76:10177-10187.
39. Cornish T.E., Stallknecht D.E., Brown C.C., Seal B.S., Howerth E.W. Pathogenesis of experimental vesicular stomatitis virus (New Jersey serotype) infection in the deer mouse (Peromyscus maniculatus). Vet. Pathol. 2001, 38:396-406.
40. Coulon P., Deutsch V., Lafay F., Martinet-Edelist C., Wyers F., Herman R.C., Flamand A. Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. J. Gen. Virol. 1990, 71(Pt 4):991-996.
41. Croyle M.A., Callahan S.M., Auricchio A., Schumer G., Linse K.D., Wilson J.M., Brunner L.J., Kobinger G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 2004, 78:912-921.
42. Cupp E.W., Mare C.J., Cupp M.S., Ramberg F.B. Biological transmission of vesicular stomatitis virus (New Jersey) by Simulium vittatum (Diptera: Simuliidae). J. Med. Entomol. 1992, 29:137-140.
43. Cureton D.K., Massol R.H., Saffarian S., Kirchhausen T.L., Whelan S.P. Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog. 2009, 5:e1000394.
44. Cureton D.K., Massol R.H., Whelan S.P., Kirchhausen T. The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis. PLoS Pathog. 2010, 6:e1001127.
45. Daffis S., Samuel M.A., Suthar M.S., Gale M., Diamond M.S. Toll-like receptor 3 has a protective role against west nile virus infection. J. Virol. 2008, 82:10349-10358.
46. Das S.C., Nayak D., Zhou Y., Pattnaik A.K. Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J. Virol. 2006, 80:6368-6377.
47. Das T., Mathur M., Gupta A.K., Janssen G.M., Banerjee A.K. RNA polymerase of vesicular stomatitis virus specifically associates with translation elongation factor-1 alphabetagamma for its activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1449-1454.
48. de la Torre J.C., Davila M., Sobrino F., Ortin J., Domingo E. Establishment of cell lines persistently infected with foot-and-mouth disease virus. Virology 1985, 145:24-35.
49. Delhaye S., Paul S., Blakqori G., Minet M., Weber F., Staeheli P., Michiels T. Neurons produce type I interferon during viral encephalitis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7835-7840.
50. Detje C.N., Meyer T., Schmidt H., Kreuz D., Rose J.K., Bechmann I., Prinz M., Kalinke U. Local type I IFN receptor signaling protects against virus spread within the central nervous system. J. Immunol. 2009, 182:2297-2304.
51. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
52. Dinh P.X., Beura L.K., Panda D., Das A., Pattnaik A.K. Antagonistic effects of cellular poly(c) binding proteins on vesicular stomatitis virus gene expression. J. Virol. 2011, 85:9459-9471.
53. Dong Y., Benveniste E.N. Immune function of astrocytes. Glia 2001, 36:180-190.
54. Doyle M., Holland J.J. Virus-induced interference in heterologously infected HeLa cells. J. Virol. 1972, 9:22-28.
55. Dreja H., Piechaczyk M. The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol. J. 2006, 3:69.
56. Drolet B.S., Campbell C.L., Stuart M.A., Wilson W.C. Vector competence of Culicoides sonorensis (Diptera: Ceratopogonidae) for vesicular stomatitis virus. J. Med. Entomol. 2005, 42:409-418.
57. Drolet B.S., Stuart M.A., Derner J.D. Infection of Melanoplus sanguinipes grasshoppers following ingestion of rangeland plant species harboring vesicular stomatitis virus. Appl. Environ. Microbiol. 2009, 75:3029-3033.
58. Dunn G.P., Sheehan K.C., Old L.J., Schreiber R.D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005, 65:3447-3453.
59. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84:443-450.
60. Edelmann K.H., Richardson-Burns S., Alexopoulou L., Tyler K.L., Flavell R.A., Oldstone M.B.A. Does Toll-like receptor 3 play a biological role in virus infections?. Virology 2004, 322:231-238.
61. Edge R.E., Falls T.J., Brown C.W., Lichty B.D., Atkins H., Bell J.C. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther. 2008, 16:1437-1443.
62. Eidelman O., Schlegel R., Tralka T.S., Blumenthal R. pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstituted into phospholipid vesicles. J. Biol. Chem. 1984, 259:4622-4628.
63. Emerson S.U., Wagner R.R. L protein requirement for in vitro RNA synthesis by vesicular stomatitis virus. J. Virol. 1973, 12:1325-1335.
64. Faria P.A., Chakraborty P., Levay A., Barber G.N., Ezelle H.J., Enninga J., Arana C., van Deursen J., Fontoura B.M. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol. Cell 2005, 17:93-102.
65. Fensterl V., Wetzel J.L., Ramachandran S., Ogino T., Stohlman S.A., Bergmann C.C., Diamond M.S., Virgin H.W., Sen G.C. Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog. 2012, 8:e1002712.
66. Fernandez M., Porosnicu M., Markovic D., Barber G.N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 2002, 76:895-904.
67. Finkelshtein D., Werman A., Novick D., Barak S., Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7306-7311.
68. Fischer H.G., Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 2001, 166:2717-2726.
69. Flanagan E.B., Zamparo J.M., Ball L.A., Rodriguez L.L., Wertz G.W. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J. Virol. 2001, 75:6107-6114.
70. Forger J.M., Bronson R.T., Huang A.S., Reiss C.S. Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system. J. Virol. 1991, 65:4950-4958.
71. Furr S.R., Chauhan V.S., Moerdyk-Schauwecker M.J., Marriott I. A role for DNA-dependent activator of interferon regulatory factor in the recognition of herpes simplex virus type 1 by glial cells. J. Neuroinflamm. 2011, 8:99.
72. Furr S.R., Chauhan V.S., Sterka D., Grdzelishvili V.Z., Marriott I. Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. J. Neurovirol. 2008, 1-11.
73. Furr S.R., Marriott I. Viral CNS infections: role of glial pattern recognition receptors in neuroinflammation. Front. Microbiol. 2012, 3:201.
74. Furr S.R., Moerdyk-Schauwecker M., Grdzelishvili V.Z., Marriott I. RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes. Glia 2010, 58:1620-1629.
75. Gaddy D.F., Lyles D.S. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J. Virol. 2005, 79:4170-4179.
76. Gaddy D.F., Lyles D.S. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J. Virol. 2007, 81:2792-2804.
77. Gao Y., Lenard J. Cooperative binding of multimeric phosphoprotein (P) of vesicular stomatitis virus to polymerase (L) and template: pathways of assembly. J. Virol. 1995, 69:7718-7723.
78. Gao Y., Whitaker-Dowling P., Watkins S.C., Griffin J.A., Bergman I. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J. Virol. 2006, 80:8603-8612.
79. Ge P., Tsao J., Schein S., Green T.J., Luo M., Zhou Z.H. Cryo-EM model of the bullet-shaped vesicular stomatitis virus. Science 2010, 327:689-693.
80. Georgel P., Jiang Z., Kunz S., Janssen E., Mols J., Hoebe K., Bahram S., Oldstone M.B., Beutler B. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 2007, 362:304-313.
81. Gillies S., Stollar V. Generation of defective interfering particles of vesicular stomatitis virus in Aedes albopictus cells. Virology 1980, 107:497-508.
82. Grdzelishvili V.Z., Smallwood S., Tower D., Hall R.L., Hunt D.M., Moyer S.A. A single amino acid change in the L-polymerase protein of vesicular stomatitis virus completely abolishes viral mRNA cap methylation. J. Virol. 2005, 79:7327-7337.
83. Grdzelishvili V.Z., Smallwood S., Tower D., Hall R.L., Hunt D.M., Moyer S.A. Identification of a new region in the vesicular stomatitis virus L polymerase protein which is essential for mRNA cap methylation. Virology 2006, 350:394-405.
84. Green T.J., Luo M. Structure of the vesicular stomatitis virus nucleocapsid in complex with the nucleocapsid-binding domain of the small polymerase cofactor, P. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11713-11718.
85. Gupta A.K., Das T., Banerjee A.K. Casein kinase II is the P protein phosphorylating cellular kinase associated with the ribonucleoprotein complex of purified vesicular stomatitis virus. J. Gen. Virol. 1995, 76(Pt 2):365-372.
86. Hall M.P., Burson K.K., Huestis W.H. Interactions of a vesicular stomatitis virus G protein fragment with phosphatidylserine: NMR and fluorescence studies. Biochim. Biophys. Acta 1998, 1415:101-113.
87. Hammond C., Helenius A. Folding of VSV G protein: sequential interaction with BiP and calnexin. Science 1994, 266:456-458.
88. Hansen D.E., Thurmond M.C., Thorburn M. Factors associated with the spread of clinical vesicular stomatitis in California dairy cattle. Am. J. Vet. Res. 1985, 46:789-795.
89. Hardy M.P., Owczarek C.M., Jermiin L.S., Ejdeback M., Hertzog P.J. Characterization of the type I interferon locus and identification of novel genes. Genomics 2004, 84:331-345.
90. Harty R.N., Brown M.E., McGettigan J.P., Wang G., Jayakar H.R., Huibregtse J.M., Whitt M.A., Schnell M.J. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J. Virol. 2001, 75:10623-10629.
91. Harty R.N., Paragas J., Sudol M., Palese P. A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J. Virol. 1999, 73:2921-2929.
92. Hastie E., Grdzelishvili V. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 2012, 93:2529-2545.
93. Heiber J.F., Barber G.N. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J. Virol. 2011, 85:10440-10450.
94. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
95. Heinrich B.S., Cureton D.K., Rahmeh A.A., Whelan S.P. Protein expression redirects vesicular stomatitis virus RNA synthesis to cytoplasmic inclusions. PLoS Pathog. 2010, 6(6):e1000958.
96. Hercyk N., Horikami S.M., Moyer S.A. The vesicular stomatitis virus L protein possesses the mRNA methyltransferase activities. Virology 1988, 163:222-225.
97. Herrmann A., Clague M.J., Puri A., Morris S.J., Blumenthal R., Grimaldi S. Effect of erythrocyte transbilayer phospholipid distribution on fusion with vesicular stomatitis virus. Biochemistry 1990, 29:4054-4058.
98. Hickey W.F., Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239:290-292.
99. Hoffmann M., Wu Y.J., Gerber M., Berger-Rentsch M., Heimrich B., Schwemmle M., Zimmer G. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. J. Gen. Virol. 2010, 91:2782-2793.
100. Holland J.J., Domingo E., de la Torre J.C., Steinhauer D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 1990, 64:3960-3962.
101. Holland J.J., Villarreal L.P., Breindl M. Factors involved in the generation and replication of rhabdovirus defective T particles. J. Virol. 1976, 17:805-815.
102. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., Endres S., Hartmann G. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
103. Huang A.S., Baltimore D. Defective viral particles and viral disease processes. Nature 1970, 226:325-327.
104. Huneycutt B.S., Bi Z., Aoki C.J., Reiss C.S. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J. Virol. 1993, 67:6698-6706.
105. Hunt D.M. Vesicular stomatitis virus mutant with altered polyadenylic acid polymerase activity in vitro. J. Virol. 1983, 46:788-799.
106. Hunt D.M. Effect of analogues of S-adenosylmethionine on in vitro polyadenylation by vesicular stomatitis virus. J. Gen. Virol. 1989, 70:535-542.
107. Hwang B.Y., Schaffer D.V. Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. Gene Ther. 2013, (Epub ahead of print).
108. Ireland D.D., Bang T., Komatsu T., Reiss C.S. Delayed administration of interleukin-12 is efficacious in promoting recovery from lethal viral encephalitis. Viral Immunol. 1999, 12:35-40.
109. Ireland D.D., Reiss C.S. Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS. Viral Immunol. 2006, 19:536-545.
110. Irie T., Liu Y., Drolet B.S., Carnero E., Garcia-Sastre A., Harty R.N. Cytopathogenesis of vesicular stomatitis virus is regulated by the PSAP motif of M protein in a species-dependent manner. Viruses 2012, 4:1605-1618.
111. Jenks N., Myers R., Greiner S.M., Thompson J., Mader E.K., Greenslade A., Griesmann G.E., Federspiel M.J., Rakela J., Borad M.J., Vile R.G., Barber G.N., Meier T.R., Blanco M.C., Carlson S.K., Russell S.J., Peng K.W. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum. Gene Ther. 2010, 21:451-462.
112. Johannsdottir H.K., Mancini R., Kartenbeck J., Amato L., Helenius A. Host cell factors and functions involved in vesicular stomatitis virus entry. J. Virol. 2009, 83:440-453.
113. Johnson J.E., Nasar F., Coleman J.W., Price R.E., Javadian A., Draper K., Lee M., Reilly P.A., Clarke D.K., Hendry R.M., Udem S.A. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360:36-49.
114. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.S., Reis e Sousa C., Matsuura Y., Fujita T., Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
115. Kelly E.J., Nace R., Barber G.N., Russell S.J. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J. Virol. 2010, 84:1550-1562.
116. Kiefer R., Lindholm D., Kreutzberg G.W. Interleukin-6 and transforming growth factor-beta 1 mRNAs are induced in rat facial nucleus following motoneuron axotomy. Eur. J. Neurosci. 1993, 5:775-781.
117. Komatsu T., Barna M., Reiss C.S. Interleukin-12 promotes recovery from viral encephalitis. Viral Immunol. 1997, 10:35-47.
118. Kopecky S.A., Lyles D.S. Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J. Virol. 2003, 77:4658-4669.
119. Kopecky S.A., Willingham M.C., Lyles D.S. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J. Virol. 2001, 75:12169-12181.
120. Kornbluth R.S., Munis J.R., Oh P.S., Meylan P.R., Richman D.D. Characterization of a macrophage-tropic HIV strain that does not alter macrophage cytokine production yet protects macrophages from superinfection by vesicular stomatitis virus. AIDS Res. Hum. Retroviruses 1990, 6:1023-1026.
121. Kwilas S., Liesman R.M., Zhang L., Walsh E., Pickles R.J., Peeples M.E. Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J. Virol. 2009, 83:10710-10718.
122. Labib M., Zamay A.S., Muharemagic D., Chechik A., Bell J.C., Berezovski M.V. Electrochemical sensing of aptamer-facilitated virus immunoshielding. Anal. Chem. 2012, 84:1677-1686.
123. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4477-4481.
124. Le Blanc I., Luyet P.P., Pons V., Ferguson C., Emans N., Petiot A., Mayran N., Demaurex N., Faure J., Sadoul R., Parton R.G., Gruenberg J. Endosome-to-cytosol transport of viral nucleocapsids. Nat. Cell Biol. 2005, 7:653-664.
125. Le Boeuf F., Diallo J.S., McCart J.A., Thorne S., Falls T., Stanford M., Kanji F., Auer R., Brown C.W., Lichty B.D., Parato K., Atkins H., Kirn D., Bell J.C. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 2010, 18:888-895.
126. Le Boeuf F., Niknejad N., Wang J., Auer R., Weberpals J.I., Bell J.C., Dimitroulakos J. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: Potential role of human papilloma virus infection. Int. J. Cancer 2012, 131:E204-E215.
127. Lee A.S., Burdeinick-Kerr R., Whelan S.P. A ribosome-specialized translation initiation pathway is required for cap-dependent translation of vesicular stomatitis virus mRNAs. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:324-329.
128. Letchworth G.J., Rodriguez L.L., Del cbarrera J. Vesicular stomatitis. Vet. J. 1999, 157:239-260.
129. Levy D.E., Marie I.J., Durbin J.E. Induction and function of type I and III interferon in response to viral infection. Curr. Opin. Virol. 2011, 1:476-486.
130. Li J., Fontaine-Rodriguez E.C., Whelan S.P. Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity. J. Virol. 2005, 79:13373-13384.
131. Li J., Rahmeh A., Morelli M., Whelan S.P. A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping. J. Virol. 2008, 82:775-784.
132. Li Q., Tainsky M.A. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One 2011, 6:e28683.
133. Li Y., Fan X., He X., Sun H., Zou Z., Yuan H., Xu H., Wang C., Shi X. MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha. Cell Mol. Immunol. 2012, 9:497-502.
134. Liang M., Yan M., Lu Y., Chen I.S. Retargeting VSV-G pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell. Hum. Gene Ther. Methods 2013.
135. Lichty B.D., Power A.T., Stojdl D.F., Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 2004, 10:210-216.
136. Lichty B.D., McBride H., Hanson S., Bell J.C. Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif. J. Gen. Virol. 2006, 87:3379-3384.
137. Linge C., Gewert D., Rossmann C., Bishop J.A., Crowe J.S. Interferon system defects in human malignant melanoma. Cancer Res. 1995, 55:4099-4104.
138. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., Iwasaki A., Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5598-5603.
139. Lyles D.S., Rupprecht C.E. Rhabdoviridae. Fields Virology 2007, 1363-1408. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. In:, P.M. Knipe, E. Howley (Eds.).
140. Marozin S., Altomonte J., Stadler F., Thasler W.E., Schmid R.M., Ebert O. Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol. Ther. 2008, 16:1789-1797.
141. Marozin S., De Toni E.N., Rizzani A., Altomonte J., Junger A., Schneider G., Thasler W.E., Kato N., Schmid R.M., Ebert O. Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS One 2010, 5:e10988.
142. Martin F.C., Anton P.A., Gornbein J.A., Shanahan F., Merrill J.E. Production of interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor. J. Neuroimmunol. 1993, 42:53-60.
143. Masters P.S., Banerjee A.K. Complex formation with vesicular stomatitis virus phosphoprotein NS prevents binding of nucleocapsid protein N to nonspecific RNA. J. Virol. 1988, 62:2658-2664.
144. Matin S.F., Rackley R.R., Sadhukhan P.C., Kim M.S., Novick A.C., Bandyopadhyay S.K. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 2001, 61:2261-2266.
145. Matlin K.S., Reggio H., Helenius A., Simons K. Pathway of vesicular stomatitis virus entry leading to infection. J. Mol. Biol. 1982, 156:609-631.
146. McKimmie C.S., Fazakerley J.K. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J. Neuroimmunol. 2005, 169:116-125.
147. Mead D.G., Gray E.W., Noblet R., Murphy M.D., Howerth E.W., Stallknecht D.E. Biological transmission of vesicular stomatitis virus (New Jersey serotype) by Simulium vittatum (Diptera: Simuliidae) to domestic swine (Sus scrofa). J. Med. Entomol. 2004, 41:78-82.
148. Mire C.E., Miller A.D., Carville A., Westmoreland S.V., Geisbert J.B., Mansfield K.G., Feldmann H., Hensley L.E., Geisbert T.W. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis. 2012, 6.
149. Mire C.E., Whitt M.A. The protease-sensitive loop of the vesicular stomatitis virus matrix protein is involved in virus assembly and protein translation. Virology 2011, 416:16-25.
150. Mishra B.B., Mishra P.K., Teale J.M. Expression and distribution of Toll-like receptors in the brain during murine neurocysticercosis. J. Neuroimmunol. 2006, 181:46-56.
151. Moerdyk-Schauwecker M., Hwang S.I., Grdzelishvili V.Z. Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach. Virol. J. 2009, 6:166.
152. Moerdyk-Schauwecker M., Shah N.R., Murphy A.M., Hastie E., Mukherjee P., Grdzelishvili V.Z. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling. Virology 2013, 436:221L 34.
153. Monsurro V., Beghelli S., Wang R., Barbi S., Coin S., Di Pasquale G., Bersani S., Castellucci M., Sorio C., Eleuteri S., Worschech A., Chiorini J.A., Pederzoli P., Alter H., Marincola F.M., Scarpa A. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J. Transl. Med. 2010, 8:10.
154. Moussavi M., Fazli L., Tearle H., Guo Y., Cox M., Bell J., Ong C., Jia W., Rennie P.S. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res. 2010, 70:1367-1376.
155. Moyer S.A., Baker S.C., Lessard J.L. Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:5405-5409.
156. Mudd J.A., Leavitt R.W., Kingsbury D.T., Holland J.J. Natural selection of mutants of vesicular stomatitis virus by cultured cells of Drosophila melanogaster. J. Gen. Virol. 1973, 20:341-351.
157. Muharemagic D., Labib M., Ghobadloo S.M., Zamay A.S., Bell J.C., Berezovski M.V. Anti-Fab aptamers for shielding virus from neutralizing antibodies. J. ACS 2012, 134:17168-17177.
158. Muik A., Dold C., Geiß Y., Volk A., Werbizki M., Dietrich U., von Laer D. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J. Mol. Med. (Berl.) 2012, 90:959L 70.
159. Muik A., Kneiske I., Werbizki M., Wilflingseder D., Giroglou T., Ebert O., Kraft A., Dietrich U., Zimmer G., Momma S., von Laer D. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J. Virol. 2011, 85:5679-5684.
160. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
161. Murphy A.M., Besmer D.M., Moerdyk-Schauwecker M., Moestl N., Ornelles D.A., Mukherjee P., Grdzelishvili V.Z. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J. Virol. 2012, 86:3073-3087.
162. Naik S., Russell S.J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert. Opin. Biol. Ther. 2009, 9:1163-1176.
163. Nazmi A., Dutta K., Basu A. RIG-I mediates innate immune response in mouse neurons following Japanese encephalitis virus infection. PloS One 2011, 6:e21761.
164. Nicholson K.G., Bauer S.P., Harrison P. Interference induced in GL-V3 monkey kidney cells by rabies virus strains. J. Gen. Virol. 1981, 53:347-351.
165. Noser J.A., Mael A.A., Sakuma R., Ohmine S., Marcato P., Lee P.W., Ikeda Y. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol. Ther. 2007, 15:1531-1536.
166. Novella I.S., Ball L.A., Wertz G.W. Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J. Virol. 2004, 78:9837-9841.
167. Novella I.S., Clarke D.K., Quer J., Duarte E.A., Lee C.H., Weaver S.C., Elena S.F., Moya A., Domingo E., Holland J.J. Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells. J. Virol. 1995, 69:6805-6809.
168. Novella I.S., Hershey C.L., Escarmis C., Domingo E., Holland J.J. Lack of evolutionary stasis during alternating replication of an arbovirus in insect and mammalian cells. J. Mol. Biol. 1999, 287:459-465.
169. Novella I.S., Presloid J.B., Zhou T., Smith-Tsurkan S.D., Ebendick-Corpus B.E., Dutta R.N., Lust K.L., Wilke C.O. Genomic evolution of vesicular stomatitis virus strains with differences in adaptability. J. Virol. 2010, 84:4960-4968.
170. Obuchi M., Fernandez M., Barber G.N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 2003, 77:8843-8856.
171. Ogino T., Banerjee A.K. Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol. Cell 2007, 25:85-97.
172. Oritani K., Kincade P.W., Zhang C., Tomiyama Y., Matsuzawa Y. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth F. R. 2001, 12:337-348.
173. Osiak A., Utermohlen O., Niendorf S., Horak I., Knobeloch K.P. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol. Cell Biol. 2005, 25:6338-6345.
174. Ostertag D., Hoblitzell-Ostertag T.M., Perrault J. Overproduction of double-stranded RNA in vesicular stomatitis virus-infected cells activates a constitutive cell-type-specific antiviral response. J. Virol. 2007, 81:503-513.
175. Otto M.J., Lucas-Lenard J. The influence of the host cell on the inhibition of virus protein synthesis in cells double infected with vesicular stomatitis virus and mengovirus. J. Gen. Virol. 1980, 50:293-307.
176. Ozduman K., Wollmann G., Piepmeier J.M., van den Pol A.N. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J. Neurosci. 2008, 28:1882-1893.
177. Ozduman K., Wollmann G., Ahmadi S.A., van den Pol A.N. Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. J. Virol. 2009, 83:11540-11549.
178. Paglino J.C., van den Pol A.N. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol. 2011, 85:9346-9358.
179. Pattnaik A.K., Hwang L., Li T., Englund N., Mathur M., Das T., Banerjee A.K. Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication. J. Virol. 1997, 71:8167-8175.
180. Pelkmans L., Fava E., Grabner H., Hannus M., Habermann B., Krausz E., Zerial M. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 2005, 436:78-86.
181. Peltier D.C., Simms A., Farmer J.R., Miller D.J. Human neuronal cells possess functional cytoplasmic and TLR-mediated innate immune pathways influenced by phosphatidylinositol-3 kinase signaling. J. Immunol. 2010, 184:7010-7021.
182. Peluso R.W., Moyer S.A. Viral proteins required for the in vitro replication of vesicular stomatitis virus defective interfering particle genome RNA. Virology 1988, 162:369-376.
183. Perrault J., Leavitt R.W. Inverted complementary terminal sequences in single-stranded RNAs and snap-back RNAs from vesicular stomatitis defective interfering particles. J. Gen. Virol. 1978, 38:35-50.
184. Pfeffer L.M., Wang C., Constantinescu S.N., Croze E., Blatt L.M., Albino A.P., Nanus D.M. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. J. Urol. 1996, 156:1867-1871.
185. Plakhov I.V., Aoki C., Reiss C.S., Huang A.S. Pathogenesis of murine encephalitis limited by defective interfering particles. An immunohistochemical study. J. Neurovirol. 1995, 1:207-218.
186. Plakhov I.V., Arlund E.E., Aoki C., Reiss C.S. The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology 1995, 209:257-262.
187. Power A.T., Bell J.C. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol. Ther. 2007, 15:660-665.
188. Preble O.T., Costello L.E., Huang D.D., Barmada M.A. Neurovirulence mutant of vesicular stomatitis virus with an altered target cell tropism in vivo. Infect. Immun. 1980, 29:744-757.
189. Prehaud C., Megret F., Lafage M., Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J. Virol. 2005, 79:12893-12904.
190. Qanungo K.R., Shaji D., Mathur M., Banerjee A.K. Two RNA polymerase complexes from vesicular stomatitis virus-infected cells that carry out transcription and replication of genome RNA. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5952-5957.
191. Quiroz E., Moreno N., Peralta P.H., Tesh R.B. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am. J. Trop. Med. Hyg. 1988, 39:312-314.
192. Rajani K.R., Pettit Kneller E.L., McKenzie M.O., Horita D.A., Chou J.W., Lyles D.S. Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription. PLoS Pathog. 2012, 8(9):e1002929.
193. Raux H., Obiang L., Richard N., Harper F., Blondel D., Gaudin Y. The matrix protein of vesicular stomatitis virus binds dynamin for efficient viral assembly. J. Virol. 2010, 84:12609-12618.
194. Rehwinkel J., Tan C.P., Goubau D., Schulz O., Pichlmair A., Bier K., Robb N., Vreede F., Barclay W., Fodor E., Reis e Sousa C. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010, 140:397-408.
195. Reif J.S., Webb P.A., Monath T.P., Emerson J.K., Poland J.D., Kemp G.E., Cholas G. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am. J. Trop. Med. Hyg. 1987, 36:177-182.
196. Reiss C.S., Plakhov I.V., Komatsu T. Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann. N. Y. Acad. Sci. 1998, 855:751-761.
197. Roche S., Albertini A.A., Lepault J., Bressanelli S., Gaudin Y. Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell Mol. Life Sci. 2008, 65:1716-1728.
198. Roth S.L., Whittaker G.R. Promotion of vesicular stomatitis virus fusion by the endosome-specific phospholipid bis(monoacylglycero)phosphate (BMP). FEBS Lett. 2011, 585:865-869.
199. Sabin L.R., Zhou R., Gruber J.J., Lukinova N., Bambina S., Berman A., Lau C.K., Thompson C.B., Cherry S. Ars2 regulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infection in Drosophila. Cell 2009, 138:340-351.
200. Saloura V., Wang L.C., Fridlender Z.G., Sun J., Cheng G., Kapoor V., Sterman D.H., Harty R.N., Okumura A., Barber G.N., Vile R.G., Federspiel M.J., Russell S.J., Litzky L., Albelda S.M. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 2010, 21:51-64.
201. Sarojini S., Theofanis T., Reiss C.S. Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol. 2011, 30:965-974.
202. Schlegel R., Tralka T.S., Willingham M.C., Pastan I. Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site?. Cell 1983, 32:639-646.
203. Schlehuber L.D., Rose J.K. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J. Virol. 2004, 78:5079-5087.
204. Schnell M.J., Buonocore L., Whitt M.A., Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 1996, 70:2318-2323.
205. Schwemmle M., Weining K.C., Richter M.F., Schumacher B., Staeheli P. Vesicular stomatitis virus transcription inhibited by purified MxA protein. Virology 1995, 206:545-554.
206. Seganti L., Superti F., Girmenia C., Melucci L., Orsi N. Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells. Microbiologica 1986, 9:259-267.
207. Sharif-Askari E., Nakhaei P., Oliere S., Tumilasci V., Hernandez E., Wilkinson P., Lin R., Bell J., Hiscott J. Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology 2007, 365:20-33.
208. Shi Z., Cai Z., Sanchez A., Zhang T., Wen S., Wang J., Yang J., Fu S., Zhang D. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J. Biol. Chem. 2011, 286:4517-4524.
209. Shinozaki K., Ebert O., Suriawinata A., Thung S.N., Woo S.L. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. J. Virol. 2005, 79:13705-13713.
210. Sleat D.E., Banerjee A.K. Transcriptional activity and mutational analysis of recombinant vesicular stomatitis virus RNA polymerase. J. Virol. 1993, 67:1334-1339.
211. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PloS Pathog. 2008, 4(3):e1000017.
212. Staeheli P., Pavlovic J. Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. J. Virol. 1991, 65:4498-4501.
213. Stanners C.P., Goldberg V.J. On the mechanism of neurotropism of vesicular stomatitis virus in newborn hamsters. Studies with temperature-sensitive mutants. J. Gen. Virol. 1975, 29:281-296.
214. Steinhauer D.A., de la Torre J.C., Holland J.J. High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus. J. Virol. 1989, 63:2063-2071.
215. Steinhauer D.A., Holland J.J. Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA. J. Virol. 1986, 57:219-228.
216. Steinhoff U., Muller U., Schertler A., Hengartner H., Aguet M., Zinkernagel R.M. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J. Virol. 1995, 69:2153-2158.
217. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
218. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., Brown E.G., Sonenberg N., Bell J.C. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 2000, 74:9580-9585.
219. Stojdl D.F., Lichty B., Tenoever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., Brown E.G., Durbin R.K., Durbin J.E., Hiscott J., Bell J.C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-275.
220. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000, 6:821-825.
221. Stoll G., Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 1999, 58:233-247.
222. Streit W.J., Semple-Rowland S.L., Hurley S.D., Miller R.C., Popovich P.G., Stokes B.T. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 1998, 152:74-87.
223. Sun W.H., Pabon C., Alsayed Y., Huang P.P., Jandeska S., Uddin S., Platanias L.C., Rosen S.T. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998, 91:570-576.
224. Sun X., Yau V.K., Briggs B.J., Whittaker G.R. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 2005, 338:53-60.
225. Superti F., Seganti L., Ruggeri F.M., Tinari A., Donelli G., Orsi N. Entry pathway of vesicular stomatitis virus into different host cells. J. Gen. Virol. 1987, 68:387-399.
226. Suthar M.S., Ma D.Y., Thomas S., Lund J.M., Zhang N., Daffis S., Rudensky A.Y., Bevan M.J., Clark E.A., Kaja M.K., Diamond M.S., Gale M. IPS-1 is essential for the control of West Nile Virus infection and immunity. PloS Pathog. 2010, 6(2):e1000757.
227. Swinteck B.D., Lyles D.S. Plasma membrane microdomains containing vesicular stomatitis virus M protein are separate from microdomains containing G protein and nucleocapsids. J. Virol. 2008, 82:5536-5547.
228. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K., Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523.
229. Tani H., Morikawa S., Matsuura Y. Development and applications of VSV vectors based on cell tropism. Front. Microbiol. 2011, 2:272.
230. Tesh R.B., Chaniotis B.N., Johnson K.M. Vesicular stomatitis virus, Indiana serotype: multiplication in and transmission by experimentally infected phlebotomine sandflies (Lutzomyia trapidoi). Am. J. Epidemiol. 1971, 93:491-495.
231. Thomsen A.R., Nansen A., Andersen C., Johansen J., Marker O., Christensen J.P. Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus. Int. Immunol. 1997, 9:1757-1766.
232. Trottier M.D., Palian B.M., Reiss C.S. VSV replication in neurons is inhibited by type I IFN at multiple stages of infection. Virology 2005, 333:215-225.
233. Trottier M.D., Lyles D.S., Reiss C.S. Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J. Neurovirol. 2007, 13:433-445.
234. Turner P.E., Elena S.F. Cost of host radiation in an RNA virus. Genetics 2000, 156:1465-1470.
235. van den Pol A.N., Dalton K.P., Rose J.K. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 2002, 76:1309-1327.
236. van den Pol A.N., Davis J.N. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J. Virol. 2013, 87:1019-1034.
237. Verheijen J.C., van der Marel G.A., van Boom J.H., Bayly S.F., Player M.R., Torrence P.F. 2,5-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L. Bioorg. Med. Chem. 1999, 7:449-455.
238. von Kobbe C., van Deursen J.M., Rodrigues J.P., Sitterlin D., Bachi A., Wu X., Wilm M., Carmo-Fonseca M., Izaurralde E. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol. Cell 2000, 6:1243-1252.
239. Waibler Z., Detje C.N., Bell J.C., Kalinke U. Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells. Immunobiology 2007, 212:887-894.
240. Wang B.X., Rahbar R., Fish E.N. Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 2011, 31:545-552.
241. Wang P.H., Arjona A., Zhang Y., Sultana H., Dai J.F., Yang L., LeBlanc P.M., Doiron K., Saleh M., Fikrig E. Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. Nat. Immunol. 2010, 11:U912-U961.
242. Weidner J.M., Jiang D., Pan X.B., Chang J., Block T.M., Guo J.T. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 2010, 84:12646-12657.
243. Wertz G.W., Moudy R., Ball L.A. Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J. Virol. 2002, 76:7642-7650.
244. Whelan S.P., Ball L.A., Barr J.N., Wertz G.T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8388-8392.
245. Whitaker-Dowling P., Youngner J.S., Widnell C.C., Wilcox D.K. Superinfection exclusion by vesicular stomatitis virus. Virology 1983, 131:137-143.
246. Whitlow Z.W., Connor J.H., Lyles D.S. Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J. Virol. 2006, 80:11733-11742.
247. Whitlow Z.W., Connor J.H., Lyles D.S. New mRNAs are preferentially translated during vesicular stomatitis virus infection. J. Virol. 2008, 82:2286-2294.
248. Wilusz J., Kurilla M.G., Keene J.D. A host protein (La) binds to a unique species of minus-sense leader RNA during replication of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:5827-5831.
249. Wollmann G., Tattersall P., van den Pol A.N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol. 2005, 79:6005-6022.
250. Wollmann G., Rogulin V., Simon I., Rose J.K., van den Pol A.N. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J. Virol. 2010, 84:1563-1573.
251. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., Edmondson S., Devenish R.J., Ralph S.J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 1997, 272:28779-28785.
252. Wu L., Huang T.G., Meseck M., Altomonte J., Ebert O., Shinozaki K., García-Sastre A., Fallon J., Mandeli J., Woo S.L. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum. Gene Ther. 2008, 19:635-647.
253. Wyers F., Blondel D., Petitjean A.M., Dezelee S. Restricted expression of viral glycoprotein in vesicular stomatitis virus-infected Drosophila melanogaster cells. J. Gen. Virol. 1989, 70:213-218.
254. Wyers F., Richard-Molard C., Blondel D., Dezelee S. Vesicular stomatitis virus growth in Drosophila melanogaster cells: G protein deficiency. J. Virol. 1980, 33:411-422.
255. Yamada S., Ohnishi S. Vesicular stomatitis virus binds and fuses with phospholipid domain in target cell membranes. Biochemistry 1986, 25:3703-3708.
256. Yoshida H., Imaizumi T., Lee S.J., Tanji K., Sakaki H., Matsumiya T., Ishikawa A., Taima K., Yuzawa E., Mori F., Wakabayashi K., Kimura H., Satoh K. Retinoic acid-inducible gene-I mediates RANTES/CCL5 expression in U373MG human astrocytoma cells stimulated with double-stranded RNA. Neurosci. Res. 2007, 58:199-206.
257. Youngner J.S., Jones E.V., Kelly M., Frielle D.W. Generation and amplification of temperature-sensitive mutants during serial undiluted passages of vesicular stomatitis virus. Virology 1981, 108:87-97.
258. Yuan H., Yoza B.K., Lyles D.S. Inhibition of host RNA polymerase II-dependent transcription by vesicular stomatitis virus results from inactivation of TFIID. Virology 1998, 251:383-392.
259. Zhang K.X., Matsui Y., Hadaschik B.A., Lee C., Jia W., Bell J.C., Fazli L., So A.I., Rennie P.S. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int. J. Cancer 2010, 127:830-838.
260. Zhao C., Denison C., Huibregtse J.M., Gygi S., Krug R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10200-10205.